{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:16:31Z","timestamp":1794492991899,"version":"4.9.1"},"reference-count":222,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"DOI":"10.1038\/s41573-026-01536-x","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:04:03Z","timestamp":1790172243000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Refining therapeutic targeting of interleukin-6 by signalling mode selectivity"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7519-3279","authenticated-orcid":false,"given":"Stefan","family":"Rose-John","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg H.","family":"Waetzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2254-7771","authenticated-orcid":false,"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"1536_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/324073a0","volume":"324","author":"T Hirano","year":"1986","unstructured":"Hirano, T. et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324, 73\u201376 (1986).","journal-title":"Nature"},{"key":"1536_CR2","doi-asserted-by":"publisher","first-page":"a028415","DOI":"10.1101\/cshperspect.a028415","volume":"10","author":"S Rose-John","year":"2018","unstructured":"Rose-John, S. Interleukin-6 family cytokines. Cold Spring Harb. Perspect. Biol. 10, a028415 (2018).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"1536_CR3","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/0167-5699(90)90139-Z","volume":"11","author":"JF Bazan","year":"1990","unstructured":"Bazan, J. F. Haemopoietic receptors and helical cytokines. Immunol. Today 11, 350\u2013354 (1990).","journal-title":"Immunol. Today"},{"key":"1536_CR4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41586-023-06816-9","volume":"625","author":"A Cui","year":"2024","unstructured":"Cui, A. et al. Dictionary of immune responses to cytokines at single-cell resolution. Nature 625, 377\u2013384 (2024).","journal-title":"Nature"},{"key":"1536_CR5","doi-asserted-by":"publisher","first-page":"813","DOI":"10.4049\/jimmunol.139.3.813","volume":"139","author":"RP Nordan","year":"1987","unstructured":"Nordan, R. P., Pumphrey, J. G. & Rudikoff, S. Purification and NH2-terminal sequence of a plasmacytoma growth factor derived from the murine macrophage cell line P388D1. J. Immunol. 139, 813\u2013817 (1987).","journal-title":"J. Immunol."},{"key":"1536_CR6","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1073\/pnas.89.1.232","volume":"89","author":"S Suematsu","year":"1992","unstructured":"Suematsu, S. et al. Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. Proc. Natl Acad. Sci. USA 89, 232\u2013235 (1992).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1536_CR7","doi-asserted-by":"publisher","first-page":"7251","DOI":"10.1073\/pnas.84.20.7251","volume":"84","author":"J Gauldie","year":"1987","unstructured":"Gauldie, J., Richards, C., Harnish, D., Lansdorp, P. & Baumann, H. Interferon beta 2\/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc. Natl Acad. Sci. USA 84, 7251\u20137255 (1987). This is, to our knowledge, the first report showing that hepatocyte-stimulating factor is identical to IL-6.","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1536_CR8","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/368339a0","volume":"368","author":"M Kopf","year":"1994","unstructured":"Kopf, M. et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368, 339\u2013342 (1994).","journal-title":"Nature"},{"key":"1536_CR9","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1182\/blood.V78.5.1198.1198","volume":"78","author":"B Klein","year":"1991","unstructured":"Klein, B. et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 78, 1198\u20131204 (1991).","journal-title":"Blood"},{"key":"1536_CR10","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1084\/jem.187.4.461","volume":"187","author":"T Alonzi","year":"1998","unstructured":"Alonzi, T. et al. Interleukin 6 is required for the development of collagen-induced arthritis. J. Exp. Med. 187, 461\u2013468 (1998).","journal-title":"J. Exp. Med."},{"key":"1536_CR11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1182\/blood.V95.1.56","volume":"95","author":"N Nishimoto","year":"2000","unstructured":"Nishimoto, N. et al. Improvement in Castleman\u2019s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95, 56\u201361 (2000).","journal-title":"Blood"},{"key":"1536_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4137\/CMAMD.S7371","volume":"5","author":"A Ogata","year":"2012","unstructured":"Ogata, A., Hirano, T., Hishitani, Y. & Tanaka, T. Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis. Clin. Med. Insights Arthritis Musculoskelet. Disord. 5, 27\u201342 (2012).","journal-title":"Clin. Med. Insights Arthritis Musculoskelet. Disord."},{"key":"1536_CR13","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nrd.2018.45","volume":"17","author":"C Garbers","year":"2018","unstructured":"Garbers, C., Heink, S., Korn, T. & Rose-John, S. Interleukin-6: designing specific therapeutics for a complex cytokine. Nat. Rev. Drug. Discov. 17, 395\u2013412 (2018).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1536_CR14","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","volume":"13","author":"KL Winthrop","year":"2017","unstructured":"Winthrop, K. L. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat. Rev. Rheumatol. 13, 234\u2013243 (2017).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1536_CR15","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41577-024-01008-6","volume":"24","author":"MF Neurath","year":"2024","unstructured":"Neurath, M. F. Strategies for targeting cytokines in inflammatory bowel disease. Nat. Rev. Immunol. 24, 559\u2013576 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"1536_CR16","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/cpt.782","volume":"102","author":"S Rose-John","year":"2017","unstructured":"Rose-John, S. The Soluble Interleukin 6 Receptor: advanced therapeutic options in inflammation. Clin. Pharmacol. Ther. 102, 591\u2013598 (2017).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1536_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13024-023-00596-6","volume":"18","author":"SA Muller","year":"2023","unstructured":"Muller, S. A. et al. The Alzheimer\u2019s disease-linked protease BACE1 modulates neuronal IL-6 signaling through shedding of the receptor gp130. Mol. Neurodegener. 18, 13 (2023).","journal-title":"Mol. Neurodegener."},{"key":"1536_CR18","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0167-4889(02)00319-1","volume":"1592","author":"SA Jones","year":"2002","unstructured":"Jones, S. A. & Rose-John, S. The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R\/IL-6 complex. Biochim. Biophys. Acta 1592, 251\u2013263 (2002).","journal-title":"Biochim. Biophys. Acta"},{"key":"1536_CR19","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/s41577-023-00856-y","volume":"23","author":"S Rose-John","year":"2023","unstructured":"Rose-John, S., Jenkins, B. J., Garbers, C., Moll, J. M. & Scheller, J. Targeting IL-6 trans-signalling: past, present and future prospects. Nat. Rev. Immunol. 23, 666\u2013681 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"1536_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev.immunol.23.021704.115806","volume":"23","author":"T Kishimoto","year":"2005","unstructured":"Kishimoto, T. Interleukin-6: from basic science to medicine-40 years in immunology. Annu. Rev. Immunol. 23, 1\u201321 (2005). This is an important review of the history of the discovery of IL-6, IL-6R, gp130, STAT3 and SOCS3 and the development of the antibody tocilizumab, which is approved in many countries for the treatment of autoimmune diseases.","journal-title":"Annu. Rev. Immunol."},{"key":"1536_CR21","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1126\/science.3136546","volume":"241","author":"K Yamasaki","year":"1988","unstructured":"Yamasaki, K. et al. Cloning and expression of the human interleukin-6 (BSF-2\/IFN beta 2) receptor. Science 241, 825\u2013828 (1988).","journal-title":"Science"},{"key":"1536_CR22","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/0092-8674(90)90411-7","volume":"63","author":"M Hibi","year":"1990","unstructured":"Hibi, M. et al. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 63, 1149\u20131157 (1990).","journal-title":"Cell"},{"key":"1536_CR23","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1146\/annurev.immunol.15.1.797","volume":"15","author":"T Taga","year":"1997","unstructured":"Taga, T. & Kishimoto, T. Gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol. 15, 797\u2013819 (1997).","journal-title":"Annu. Rev. Immunol."},{"key":"1536_CR24","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/eji.1830230226","volume":"23","author":"J Mullberg","year":"1993","unstructured":"Mullberg, J. et al. The soluble interleukin-6 receptor is generated by shedding. Eur. J. Immunol. 23, 473\u2013480 (1993). This is, to our knowledge, the first study to describe the shedding of the IL-6R and the biological activity of the soluble IL-6R.","journal-title":"Eur. J. Immunol."},{"key":"1536_CR25","doi-asserted-by":"publisher","first-page":"38829","DOI":"10.1074\/jbc.M210584200","volume":"278","author":"V Matthews","year":"2003","unstructured":"Matthews, V. et al. Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J. Biol. Chem. 278, 38829\u201338839 (2003).","journal-title":"J. Biol. Chem."},{"key":"1536_CR26","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.4049\/jimmunol.149.6.2021","volume":"149","author":"A Mackiewicz","year":"1992","unstructured":"Mackiewicz, A., Schooltink, H., Heinrich, P. C. & Rose-John, S. Complex of soluble human IL-6-receptor\/IL-6 up-regulates expression of acute-phase proteins. J. Immunol. 149, 2021\u20132027 (1992).","journal-title":"J. Immunol."},{"key":"1536_CR27","doi-asserted-by":"publisher","first-page":"22084","DOI":"10.1016\/S0021-9258(20)80651-6","volume":"268","author":"S Rose-John","year":"1993","unstructured":"Rose-John, S. et al. Intracellular retention of interleukin-6 abrogates signaling. J. Biol. Chem. 268, 22084\u201322091 (1993).","journal-title":"J. Biol. Chem."},{"key":"1536_CR28","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190347","volume":"217","author":"S Kang","year":"2020","unstructured":"Kang, S., Narazaki, M., Metwally, H. & Kishimoto, T. Historical overview of the interleukin-6 family cytokine. J. Exp. Med. 217, e20190347 (2020).","journal-title":"J. Exp. Med."},{"key":"1536_CR29","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1042\/bj3000281","volume":"300","author":"S Rose-John","year":"1994","unstructured":"Rose-John, S. & Heinrich, P. C. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem. J. 300, 281\u2013290 (1994). In this article, the paradigm of IL-6 signalling via the soluble IL-6R and the term trans-signalling are suggested.","journal-title":"Biochem. J."},{"key":"1536_CR30","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1182\/blood.V82.4.1120.1120","volume":"82","author":"M Narazaki","year":"1993","unstructured":"Narazaki, M. et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 82, 1120\u20131126 (1993).","journal-title":"Blood"},{"key":"1536_CR31","doi-asserted-by":"publisher","first-page":"16186","DOI":"10.1074\/jbc.M116.718551","volume":"291","author":"J Wolf","year":"2016","unstructured":"Wolf, J. et al. Different soluble forms of the interleukin-6 family signal transducer gp130 fine-tune the blockade of interleukin-6 trans-signaling. J. Biol. Chem. 291, 16186\u201316196 (2016).","journal-title":"J. Biol. Chem."},{"key":"1536_CR32","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1046\/j.1432-1327.2001.01867.x","volume":"268","author":"T Jostock","year":"2001","unstructured":"Jostock, T. et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur. J. Biochem. 268, 160\u2013167 (2001). This study demonstrates that the soluble form of gp130, found at high concentrations in human serum, is a specific inhibitor of IL-6 trans-signalling, and describes the construction and testing of the sgp130Fc protein.","journal-title":"Eur. J. Biochem."},{"key":"1536_CR33","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1002\/art.21818","volume":"54","author":"PJ Richards","year":"2006","unstructured":"Richards, P. J. et al. Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthritis Rheum. 54, 1662\u20131672 (2006).","journal-title":"Arthritis Rheum."},{"key":"1536_CR34","doi-asserted-by":"publisher","first-page":"E411","DOI":"10.1152\/ajpendo.00166.2019","volume":"317","author":"S Aparicio-Siegmund","year":"2019","unstructured":"Aparicio-Siegmund, S. et al. The IL-6-neutralizing sIL-6R-sgp130 buffer system is disturbed in patients with type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 317, E411\u2013E420 (2019).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"1536_CR35","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/ni.3632","volume":"18","author":"S Heink","year":"2017","unstructured":"Heink, S. et al. Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells. Nat. Immunol. 18, 74\u201385 (2017). This study reports IL-6 trans-presentation as an additional signalling paradigm.","journal-title":"Nat. Immunol."},{"key":"1536_CR36","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.celrep.2014.07.008","volume":"8","author":"JP Bottcher","year":"2014","unstructured":"Bottcher, J. P. et al. IL-6 trans-signaling-dependent rapid development of cytotoxic CD8+ T cell function. Cell Rep. 8, 1318\u20131327 (2014).","journal-title":"Cell Rep."},{"key":"1536_CR37","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.4049\/jimmunol.153.4.1744","volume":"153","author":"M Ehlers","year":"1994","unstructured":"Ehlers, M. et al. Identification of two novel regions of human IL-6 responsible for receptor binding and signal transduction. J. Immunol. 153, 1744\u20131753 (1994).","journal-title":"J. Immunol."},{"key":"1536_CR38","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1002\/j.1460-2075.1994.tb06389.x","volume":"13","author":"R Savino","year":"1994","unstructured":"Savino, R. et al. Generation of interleukin-6 receptor antagonists by molecular-modeling guided mutagenesis of residues important for gp130 activation. EMBO J. 13, 1357\u20131367 (1994).","journal-title":"EMBO J."},{"key":"1536_CR39","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.cytogfr.2015.07.004","volume":"26","author":"F Schaper","year":"2015","unstructured":"Schaper, F. & Rose-John, S. Interleukin-6: biology, signaling and strategies of blockade. Cytokine Growth Factor. Rev. 26, 475\u2013487 (2015).","journal-title":"Cytokine Growth Factor. Rev."},{"key":"1536_CR40","doi-asserted-by":"publisher","first-page":"274","DOI":"10.4049\/jimmunol.2300114","volume":"211","author":"D Millrine","year":"2023","unstructured":"Millrine, D. et al. Th1 cells alter the inflammatory signature of IL-6 by channeling STAT transcription factors to Alu-like retroelements. J. Immunol. 211, 274\u2013286 (2023).","journal-title":"J. Immunol."},{"key":"1536_CR41","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1111\/febs.16420","volume":"290","author":"A McFarlane","year":"2023","unstructured":"McFarlane, A., Pohler, E. & Moraga, I. Molecular and cellular factors determining the functional pleiotropy of cytokines. FEBS J. 290, 2525\u20132552 (2023).","journal-title":"FEBS J."},{"key":"1536_CR42","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1084\/jem.191.6.915","volume":"191","author":"TK Teague","year":"2000","unstructured":"Teague, T. K. et al. Activation-induced inhibition of interleukin 6-mediated T cell survival and signal transducer and activator of transcription 1 signaling. J. Exp. Med. 191, 915\u2013926 (2000).","journal-title":"J. Exp. Med."},{"key":"1536_CR43","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.immuni.2019.03.026","volume":"50","author":"S Kang","year":"2019","unstructured":"Kang, S., Tanaka, T., Narazaki, M. & Kishimoto, T. Targeting interleukin-6 signaling in clinic. Immunity 50, 1007\u20131023 (2019).","journal-title":"Immunity"},{"key":"1536_CR44","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41590-019-0350-0","volume":"20","author":"JP Twohig","year":"2019","unstructured":"Twohig, J. P. et al. Activation of naive CD4+ T cells re-tunes STAT1 signaling to deliver unique cytokine responses in memory CD4+ T cells. Nat. Immunol. 20, 458\u2013470 (2019).","journal-title":"Nat. Immunol."},{"key":"1536_CR45","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/0014-5793(92)81004-6","volume":"306","author":"D Zohlnhofer","year":"1992","unstructured":"Zohlnhofer, D. et al. The hepatic interleukin-6 receptor. Down-regulation of the interleukin-6 binding subunit (gp80) by its ligand. FEBS Lett. 306, 219\u2013222 (1992).","journal-title":"FEBS Lett."},{"key":"1536_CR46","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.4049\/jimmunol.161.7.3575","volume":"161","author":"M Peters","year":"1998","unstructured":"Peters, M. et al. In vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6. J. Immunol. 161, 3575\u20133581 (1998).","journal-title":"J. Immunol."},{"key":"1536_CR47","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1432-1033.1990.tb15548.x","volume":"190","author":"S Rose-John","year":"1990","unstructured":"Rose-John, S. et al. Studies on the structure and regulation of the human hepatic interleukin-6 receptor. Eur. J. Biochem. 190, 79\u201383 (1990).","journal-title":"Eur. J. Biochem."},{"key":"1536_CR48","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1182\/blood.V92.10.3495","volume":"92","author":"M Peters","year":"1998","unstructured":"Peters, M., Muller, A. M. & Rose-John, S. Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. Blood 92, 3495\u20133504 (1998).","journal-title":"Blood"},{"key":"1536_CR49","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1084\/jem.20190344","volume":"216","author":"S Spencer","year":"2019","unstructured":"Spencer, S. et al. Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses. J. Exp. Med. 216, 1986\u20131998 (2019).","journal-title":"J. Exp. Med."},{"key":"1536_CR50","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.jaci.2019.11.015","volume":"145","author":"A Nahum","year":"2020","unstructured":"Nahum, A. et al. Defining the biological responses of IL-6 by the study of a novel IL-6 receptor chain immunodeficiency. J. Allergy Clin. Immunol. 145, 1011\u20131015 e1016 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1536_CR51","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1073\/pnas.93.1.407","volume":"93","author":"K Yoshida","year":"1996","unstructured":"Yoshida, K. et al. Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc. Natl Acad. Sci. USA 93, 407\u2013411 (1996).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1536_CR52","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191306","volume":"217","author":"YH Chen","year":"2020","unstructured":"Chen, Y. H. et al. Absence of GP130 cytokine receptor signaling causes extended Stuve\u2013Wiedemann syndrome. J. Exp. Med. 217, e20191306 (2020).","journal-title":"J. Exp. Med."},{"key":"1536_CR53","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/ni.2137","volume":"12","author":"H Iwasaki","year":"2011","unstructured":"Iwasaki, H. et al. The IkappaB kinase complex regulates the stability of cytokine-encoding mRNA induced by TLR-IL-1R by controlling degradation of regnase-1. Nat. Immunol. 12, 1167\u20131175 (2011).","journal-title":"Nat. Immunol."},{"key":"1536_CR54","doi-asserted-by":"publisher","first-page":"9409","DOI":"10.1073\/pnas.1307419110","volume":"110","author":"K Masuda","year":"2013","unstructured":"Masuda, K. et al. Arid5a controls IL-6 mRNA stability, which contributes to elevation of IL-6 level in vivo. Proc. Natl Acad. Sci. USA 110, 9409\u20139414 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1536_CR55","doi-asserted-by":"publisher","first-page":"827611","DOI":"10.3389\/fimmu.2021.827611","volume":"12","author":"KK Nyati","year":"2021","unstructured":"Nyati, K. K. & Kishimoto, T. Recent advances in the role of arid5a in immune diseases and cancer. Front. Immunol. 12, 827611 (2021).","journal-title":"Front. Immunol."},{"key":"1536_CR56","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1146\/annurev-immunol-101220-023458","volume":"40","author":"T Kishimoto","year":"2022","unstructured":"Kishimoto, T. & Kang, S. IL-6 Revisited: from rheumatoid arthritis to CAR T cell therapy and COVID-19. Annu. Rev. Immunol. 40, 323\u2013348 (2022).","journal-title":"Annu. Rev. Immunol."},{"key":"1536_CR57","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/ni.3153","volume":"16","author":"CA Hunter","year":"2015","unstructured":"Hunter, C. A. & Jones, S. A. IL-6 as a keystone cytokine in health and disease. Nat. Immunol. 16, 448\u2013457 (2015).","journal-title":"Nat. Immunol."},{"key":"1536_CR58","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1056\/NEJM199902113400607","volume":"340","author":"C Gabay","year":"1999","unstructured":"Gabay, C. & Kushner, I. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 340, 448\u2013454 (1999).","journal-title":"N. Engl. J. Med."},{"key":"1536_CR59","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1053\/gast.1996.v110.pm8964411","volume":"110","author":"C Trautwein","year":"1996","unstructured":"Trautwein, C., Rakemann, T., Niehof, M., Rose-John, S. & Manns, M. P. Acute-phase response factor, increased binding, and target gene transcription during liver regeneration. Gastroenterology 110, 1854\u20131862 (1996).","journal-title":"Gastroenterology"},{"key":"1536_CR60","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1053\/gast.2000.20236","volume":"119","author":"M Peters","year":"2000","unstructured":"Peters, M. et al. Combined interleukin 6 and soluble interleukin 6 receptor accelerates murine liver regeneration. Gastroenterology 119, 1663\u20131671 (2000).","journal-title":"Gastroenterology"},{"key":"1536_CR61","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1126\/science.274.5291.1379","volume":"274","author":"DE Cressman","year":"1996","unstructured":"Cressman, D. E. et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 274, 1379\u20131383 (1996). This study shows the dependence of liver regeneration on IL-6.","journal-title":"Science"},{"key":"1536_CR62","doi-asserted-by":"publisher","first-page":"eadf4490","DOI":"10.1126\/sciadv.adf4490","volume":"9","author":"M Carbonaro","year":"2023","unstructured":"Carbonaro, M. et al. IL-6-GP130 signaling protects human hepatocytes against lipid droplet accumulation in humanized liver models. Sci. Adv. 9, eadf4490 (2023). The study describes that IL-6 in hepatocytes prevents lipid accumulation in vivo.","journal-title":"Sci. Adv."},{"key":"1536_CR63","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/nm0102-75","volume":"8","author":"V Wallenius","year":"2002","unstructured":"Wallenius, V. et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat. Med. 8, 75\u201379 (2002). This study finds that Il6-deficient mice develop mature-onset obesity.","journal-title":"Nat. Med."},{"key":"1536_CR64","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature04753","volume":"441","author":"E Bettelli","year":"2006","unstructured":"Bettelli, E. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235\u2013238 (2006).","journal-title":"Nature"},{"key":"1536_CR65","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1016\/j.cell.2020.12.008","volume":"183","author":"JY Lee","year":"2020","unstructured":"Lee, J. Y. et al. Serum amyloid A proteins induce pathogenic Th17 cells and promote inflammatory disease. Cell 183, 2036\u20132039 (2020). This study reports that the acute phase protein serum amyloid A is a differentiation factor for TH17 cells.","journal-title":"Cell"},{"key":"1536_CR66","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1046\/j.1432-1327.1999.00657.x","volume":"265","author":"CM Uhlar","year":"1999","unstructured":"Uhlar, C. M. & Whitehead, A. S. Serum amyloid A, the major vertebrate acute-phase reactant. Eur. J. Biochem. 265, 501\u2013523 (1999).","journal-title":"Eur. J. Biochem."},{"key":"1536_CR67","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/intimm\/10.5.703","volume":"10","author":"Y Okuda","year":"1998","unstructured":"Okuda, Y. et al. IL-6-deficient mice are resistant to the induction of experimental autoimmune encephalomyelitis provoked by myelin oligodendrocyte glycoprotein. Int. Immunol. 10, 703\u2013708 (1998).","journal-title":"Int. Immunol."},{"key":"1536_CR68","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1126\/science.1208421","volume":"334","author":"JA Harker","year":"2011","unstructured":"Harker, J. A., Lewis, G. M., Mack, L. & Zuniga, E. I. Late interleukin-6 escalates T follicular helper cell responses and controls a chronic viral infection. Science 334, 825\u2013829 (2011).","journal-title":"Science"},{"key":"1536_CR69","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.4049\/jimmunol.141.5.1543","volume":"141","author":"M Okada","year":"1988","unstructured":"Okada, M. et al. IL-6\/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J. Immunol. 141, 1543\u20131549 (1988).","journal-title":"J. Immunol."},{"key":"1536_CR70","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature14228","volume":"519","author":"K Taniguchi","year":"2015","unstructured":"Taniguchi, K. et al. A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature 519, 57\u201362 (2015).","journal-title":"Nature"},{"key":"1536_CR71","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ccr.2009.01.001","volume":"15","author":"S Grivennikov","year":"2009","unstructured":"Grivennikov, S. et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15, 103\u2013113 (2009). This article demonstrated that IL-6 has anti-inflammatory activity in a mouse model of inflammatory bowel disease.","journal-title":"Cancer Cell"},{"key":"1536_CR72","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41586-025-09395-z","volume":"646","author":"C Llorente","year":"2025","unstructured":"Llorente, C. et al. mAChR4 suppresses liver disease via GAP-induced antimicrobial immunity. Nature 646, 180\u2013189 (2025).","journal-title":"Nature"},{"key":"1536_CR73","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","volume":"6","author":"DT Teachey","year":"2016","unstructured":"Teachey, D. T. et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic Leukemia. Cancer Discov. 6, 664\u2013679 (2016).","journal-title":"Cancer Discov."},{"key":"1536_CR74","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1126\/science.abb8925","volume":"368","author":"JB Moore","year":"2020","unstructured":"Moore, J. B. & June, C. H. Cytokine release syndrome in severe COVID-19. Science 368, 473\u2013474 (2020).","journal-title":"Science"},{"key":"1536_CR75","doi-asserted-by":"publisher","first-page":"1488745","DOI":"10.3389\/fimmu.2024.1488745","volume":"15","author":"J Lokau","year":"2024","unstructured":"Lokau, J. et al. Long-term increase in soluble interleukin-6 receptor levels in convalescents after mild COVID-19 infection. Front. Immunol. 15, 1488745 (2024).","journal-title":"Front. Immunol."},{"key":"1536_CR76","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","volume":"384","author":"REMAP-CAP Investigators","year":"2021","unstructured":"REMAP-CAP Investigators et al. Interleukin-6 receptor antagonists in critically ill patients with covid-19. N. Engl. J. Med. 384, 1491\u20131502 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1536_CR77","doi-asserted-by":"publisher","first-page":"105132","DOI":"10.1016\/j.ebiom.2024.105132","volume":"103","author":"MA Rodriguez-Hernandez","year":"2024","unstructured":"Rodriguez-Hernandez, M. A. et al. Targeting IL-6 trans-signalling by sgp130Fc attenuates severity in SARS-CoV-2 -infected mice and reduces endotheliopathy. EBioMedicine 103, 105132 (2024).","journal-title":"EBioMedicine"},{"key":"1536_CR78","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/75068","volume":"6","author":"R Atreya","year":"2000","unstructured":"Atreya, R. et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat. Med. 6, 583\u2013588 (2000). This is, to our knowledge, the first study to describe that blockade of IL-6 trans-signalling efficiently blocks inflammatory bowel disease in mice.","journal-title":"Nat. Med."},{"key":"1536_CR79","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1136\/gut.2005.079343","volume":"55","author":"K Mitsuyama","year":"2006","unstructured":"Mitsuyama, K. et al. STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1\/Yit mice. Gut 55, 1263\u20131269 (2006).","journal-title":"Gut"},{"key":"1536_CR80","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.immuni.2004.07.020","volume":"21","author":"C Becker","year":"2004","unstructured":"Becker, C. et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21, 491\u2013501 (2004).","journal-title":"Immunity"},{"key":"1536_CR81","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.4049\/jimmunol.0801217","volume":"184","author":"S Matsumoto","year":"2010","unstructured":"Matsumoto, S. et al. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6\/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J. Immunol. 184, 1543\u20131551 (2010).","journal-title":"J. Immunol."},{"key":"1536_CR82","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1084\/jem.20171696","volume":"215","author":"S Schmidt","year":"2018","unstructured":"Schmidt, S. et al. ADAM17 is required for EGF-R-induced intestinal tumors via IL-6 trans-signaling. J. Exp. Med. 215, 1205\u20131225 (2018).","journal-title":"J. Exp. Med."},{"key":"1536_CR83","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1681\/ASN.2014060620","volume":"26","author":"M Luig","year":"2015","unstructured":"Luig, M. et al. Inflammation-Induced IL-6 functions as a natural brake on macrophages and limits GN. J. Am. Soc. Nephrol. 26, 1597\u20131607 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1536_CR84","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1681\/ASN.2014111147","volume":"27","author":"GS Braun","year":"2016","unstructured":"Braun, G. S. et al. IL-6 Trans-Signaling drives murine crescentic GN. J. Am. Soc. Nephrol. 27, 132\u2013142 (2016).","journal-title":"Am. Soc. Nephrol."},{"key":"1536_CR85","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1093\/rheumatology\/kes403","volume":"52","author":"Y Matsuo","year":"2013","unstructured":"Matsuo, Y. et al. Tocilizumab-induced immune complex glomerulonephritis in a patient with rheumatoid arthritis. Rheumatology 52, 1341\u20131343 (2013).","journal-title":"Rheumatology"},{"key":"1536_CR86","doi-asserted-by":"publisher","first-page":"8222","DOI":"10.1073\/pnas.95.14.8222","volume":"95","author":"S Ohshima","year":"1998","unstructured":"Ohshima, S. et al. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc. Natl Acad. Sci. USA 95, 8222\u20138226 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1536_CR87","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/nbt0297-142","volume":"15","author":"M Fischer","year":"1997","unstructured":"Fischer, M. et al. I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat. Biotechnol. 15, 142\u2013145 (1997). This is, to our knowledge, the first description of the designer cytokine hyper-IL-6, a fusion protein of IL-6 and sIL-6R, which can be used to mimic IL-6 trans-signalling in vitro and in vivo.","journal-title":"Nat. Biotechnol."},{"key":"1536_CR88","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.4049\/jimmunol.171.6.3202","volume":"171","author":"MA Nowell","year":"2003","unstructured":"Nowell, M. A. et al. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J. Immunol. 171, 3202\u20133209 (2003).","journal-title":"J. Immunol."},{"key":"1536_CR89","doi-asserted-by":"publisher","first-page":"613","DOI":"10.4049\/jimmunol.182.1.613","volume":"182","author":"MA Nowell","year":"2009","unstructured":"Nowell, M. A. et al. Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. J. Immunol. 182, 613\u2013622 (2009).","journal-title":"J. Immunol."},{"key":"1536_CR90","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1161\/ATVBAHA.111.229435","volume":"32","author":"H Schuett","year":"2012","unstructured":"Schuett, H. et al. Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. 32, 281\u2013290 (2012).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1536_CR91","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2353\/ajpath.2007.061078","volume":"171","author":"B Coles","year":"2007","unstructured":"Coles, B. et al. Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo. Am. J. Pathol. 171, 315\u2013325 (2007).","journal-title":"Am. J. Pathol."},{"key":"1536_CR92","doi-asserted-by":"publisher","first-page":"758233","DOI":"10.3389\/fphar.2022.758233","volume":"13","author":"DM Schulte","year":"2022","unstructured":"Schulte, D. M. et al. Case report: arterial wall inflammation in atherosclerotic cardiovascular disease is reduced by olamkicept (sgp130Fc). Front. Pharmacol. 13, 758233 (2022). In this case report, treatment of a patient with very high risk atherosclerotic cardiovascular disease with olamkicept resulted in reduced arterial wall inflammation.","journal-title":"Front. Pharmacol."},{"key":"1536_CR93","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jacbts.2021.01.013","volume":"6","author":"MJ George","year":"2021","unstructured":"George, M. J. et al. Selective interleukin-6 trans-signaling blockade is more effective than panantagonism in reperfused myocardial infarction. JACC Basic. Transl. Sci. 6, 431\u2013443 (2021). This paper provides evidence that specific blockade of IL-6 trans-signalling but not global IL-6 blockade is beneficial for the treatment of myocardial infarction in rats.","journal-title":"JACC Basic. Transl. Sci."},{"key":"1536_CR94","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1003444","volume":"9","author":"RC Ferreira","year":"2013","unstructured":"Ferreira, R. C. et al. Functional IL6R 358Ala allele impairs classical IL-6 receptor signaling and influences risk of diverse inflammatory diseases. PLoS Genet. 9, e1003444 (2013).","journal-title":"PLoS Genet."},{"key":"1536_CR95","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.118.002413","volume":"12","author":"E Paige","year":"2019","unstructured":"Paige, E. et al. Interleukin-6 receptor signaling and abdominal aortic aneurysm growth rates. Circ. Genom. Precis. Med. 12, e002413 (2019).","journal-title":"Circ. Genom. Precis. Med."},{"key":"1536_CR96","doi-asserted-by":"publisher","first-page":"502","DOI":"10.7326\/0003-4819-122-7-199504010-00004","volume":"122","author":"JM Evans","year":"1995","unstructured":"Evans, J. M., O\u2019Fallon, W. M. & Hunder, G. G. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann. Intern. Med. 122, 502\u2013507 (1995).","journal-title":"Ann. Intern. Med."},{"key":"1536_CR97","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1007\/s10067-016-3372-0","volume":"35","author":"O Shovman","year":"2016","unstructured":"Shovman, O. et al. Aortic aneurysm associated with rheumatoid arthritis: a population-based cross-sectional study. Clin. Rheumatol. 35, 2657\u20132661 (2016).","journal-title":"Clin. Rheumatol."},{"key":"1536_CR98","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1172\/JCI64931","volume":"123","author":"H Zhang","year":"2013","unstructured":"Zhang, H. et al. IL-6 trans-signaling promotes pancreatitis-associated lung injury and lethality. J. Clin. Invest. 123, 1019\u20131031 (2013).","journal-title":"J. Clin. Invest."},{"key":"1536_CR99","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/j.1460-2075.1994.tb06368.x","volume":"13","author":"V Poli","year":"1994","unstructured":"Poli, V. et al. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 13, 1189\u20131196 (1994).","journal-title":"EMBO J."},{"key":"1536_CR100","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00210-018-1483-7","volume":"391","author":"K Kaiser","year":"2018","unstructured":"Kaiser, K. et al. Pharmacological inhibition of IL-6 trans-signaling improves compromised fracture healing after severe trauma. Naunyn Schmiedebergs Arch. Pharmacol. 391, 523\u2013536 (2018).","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"1536_CR101","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ajpath.2017.10.011","volume":"188","author":"K Prystaz","year":"2018","unstructured":"Prystaz, K. et al. Distinct effects of IL-6 classic and trans-signaling in bone fracture healing. Am. J. Pathol. 188, 474\u2013490 (2018).","journal-title":"Am. J. Pathol."},{"key":"1536_CR102","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S1074-7613(01)00151-0","volume":"14","author":"SM Hurst","year":"2001","unstructured":"Hurst, S. M. et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 14, 705\u2013714 (2001).","journal-title":"Immunity"},{"key":"1536_CR103","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.immuni.2013.10.022","volume":"40","author":"CA Fielding","year":"2014","unstructured":"Fielding, C. A. et al. Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity 40, 40\u201350 (2014).","journal-title":"Immunity"},{"key":"1536_CR104","doi-asserted-by":"publisher","first-page":"120136","DOI":"10.1016\/j.bbamcr.2026.120136","volume":"1873","author":"F Monaco","year":"2026","unstructured":"Monaco, F., Dimonte, S. & Jones, S. A. The role of IL-6 in rheumatoid arthritis comorbidity and implications for therapy. Biochim. Biophys. Acta. Mol. Cell Res. 1873, 120136 (2026).","journal-title":"Biochim. Biophys. Acta. Mol. Cell Res."},{"key":"1536_CR105","doi-asserted-by":"publisher","first-page":"703","DOI":"10.4049\/jimmunol.1201044","volume":"190","author":"J Hoge","year":"2013","unstructured":"Hoge, J. et al. IL-6 controls the innate immune response against Listeria monocytogenes via classical IL-6 signaling. J. Immunol. 190, 703\u2013711 (2013). This article shows that IL-6 protection from bacterial infection is mediated by classic signalling via the membrane-bound IL-6R.","journal-title":"J. Immunol."},{"key":"1536_CR106","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.imbio.2012.01.015","volume":"217","author":"J Sodenkamp","year":"2012","unstructured":"Sodenkamp, J. et al. Therapeutic targeting of interleukin-6 trans-signaling does not affect the outcome of experimental tuberculosis. Immunobiology 217, 996\u20131004 (2012).","journal-title":"Immunobiology"},{"key":"1536_CR107","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1084\/jem.169.1.333","volume":"169","author":"A Waage","year":"1989","unstructured":"Waage, A., Brandtzaeg, P., Halstensen, A., Kierulf, P. & Espevik, T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J. Exp. Med. 169, 333\u2013338 (1989).","journal-title":"J. Exp. Med."},{"key":"1536_CR108","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1097\/CCM.0b013e318211ff56","volume":"39","author":"T Barkhausen","year":"2011","unstructured":"Barkhausen, T. et al. Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model. Crit. Care Med. 39, 1407\u20131413 (2011). This study shows that blockade of IL-6 trans-signalling but not global blockade of IL-6 prevents sepsis in mice.","journal-title":"Crit. Care Med."},{"key":"1536_CR109","doi-asserted-by":"publisher","unstructured":"Liu, X. et al. Regulation of inflammatory responses and apoptosis: sgp130fc as a potential therapeutic agent for sepsis-associated kidney injury. Shock https:\/\/doi.org\/10.1097\/SHK.0000000000002843 (2026).","DOI":"10.1097\/SHK.0000000000002843"},{"key":"1536_CR110","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1038\/s41467-026-70451-x","volume":"17","author":"W Yan","year":"2026","unstructured":"Yan, W. et al. Extracellular vesicle engineering using a small scaffold protein. Nat. Commun. 17, 3726 (2026).","journal-title":"Nat. Commun."},{"key":"1536_CR111","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ccr.2011.03.009","volume":"19","author":"M Lesina","year":"2011","unstructured":"Lesina, M. et al. Stat3\/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19, 456\u2013469 (2011).","journal-title":"Cancer Cell"},{"key":"1536_CR112","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1158\/0008-5472.CAN-15-2388","volume":"76","author":"GD Brooks","year":"2016","unstructured":"Brooks, G. D. et al. IL6 trans-signaling promotes KRAS-driven lung carcinogenesis. Cancer Res. 76, 866\u2013876 (2016).","journal-title":"Cancer Res."},{"key":"1536_CR113","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/hep.28874","volume":"65","author":"J Bergmann","year":"2017","unstructured":"Bergmann, J. et al. IL-6 trans-signaling is essential for the development of hepatocellular carcinoma in mice. Hepatology 65, 89\u2013103 (2017).","journal-title":"Hepatology"},{"key":"1536_CR114","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1016\/j.jhep.2022.07.029","volume":"77","author":"N Rosenberg","year":"2022","unstructured":"Rosenberg, N. et al. Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling. J. Hepatol. 77, 1631\u20131641 (2022).","journal-title":"J. Hepatol."},{"key":"1536_CR115","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.3389\/fimmu.2020.01424","volume":"11","author":"RD Metcalfe","year":"2020","unstructured":"Metcalfe, R. D., Putoczki, T. L. & Griffin, M. D. W. Structural understanding of interleukin 6 family cytokine signaling and targeted therapies: focus on interleukin 11. Front. Immunol. 11, 1424 (2020).","journal-title":"Front. Immunol."},{"key":"1536_CR116","doi-asserted-by":"publisher","first-page":"eabc3480","DOI":"10.1126\/scisignal.abc3480","volume":"14","author":"D Heise","year":"2021","unstructured":"Heise, D. et al. Selective inhibition of IL-6 trans-signaling by a miniaturized, optimized chimeric soluble gp130 inhibits TH17 cell expansion. Sci. Signal. 14, eabc3480 (2021).","journal-title":"Sci. Signal."},{"key":"1536_CR117","doi-asserted-by":"publisher","first-page":"103309","DOI":"10.1016\/j.isci.2021.103309","volume":"24","author":"J Lokau","year":"2021","unstructured":"Lokau, J., Garbers, Y., Grotzinger, J. & Garbers, C. A single aromatic residue in sgp130Fc\/olamkicept allows the discrimination between interleukin-6 and interleukin-11 trans-signaling. iScience 24, 103309 (2021).","journal-title":"iScience"},{"key":"1536_CR118","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1172\/JCI57158","volume":"121","author":"SA Jones","year":"2011","unstructured":"Jones, S. A., Scheller, J. & Rose-John, S. Therapeutic strategies for the clinical blockade of IL-6\/gp130 signaling. J. Clin. Invest. 121, 3375\u20133383 (2011).","journal-title":"J. Clin. Invest."},{"key":"1536_CR119","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/psp4.12534","volume":"9","author":"P Kovalenko","year":"2020","unstructured":"Kovalenko, P. et al. Population pharmacodynamic model of neutrophil margination and tolerance to describe effect of sarilumab on absolute neutrophil count in patients with rheumatoid arthritis. CPT Pharmacomet. Syst. Pharmacol. 9, 405\u2013416 (2020).","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"1536_CR120","doi-asserted-by":"publisher","first-page":"R141","DOI":"10.1186\/ar3455","volume":"13","author":"MH Schiff","year":"2011","unstructured":"Schiff, M. H. et al. Integrated safety in tocilizumab clinical trials. Arthritis Res. Ther. 13, R141 (2011).","journal-title":"Arthritis Res. Ther."},{"key":"1536_CR121","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s40262-019-00765-1","volume":"58","author":"C Xu","year":"2019","unstructured":"Xu, C., Su, Y., Paccaly, A. & Kanamaluru, V. Population pharmacokinetics of sarilumab in patients with rheumatoid arthritis. Clin. Pharmacokinet. 58, 1455\u20131467 (2019).","journal-title":"Clin. Pharmacokinet."},{"key":"1536_CR122","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/BOR.0000000000000496","volume":"30","author":"TD Mahajan","year":"2018","unstructured":"Mahajan, T. D. & Mikuls, T. R. Recent advances in the treatment of rheumatoid arthritis. Curr. Opin. Rheumatol. 30, 231\u2013237 (2018).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1536_CR123","doi-asserted-by":"publisher","first-page":"e380","DOI":"10.1093\/cid\/ciac153","volume":"75","author":"S Sivapalasingam","year":"2022","unstructured":"Sivapalasingam, S. et al. Efficacy and safety of sarilumab in hospitalized patients with coronavirus disease 2019: a randomized clinical trial. Clin. Infect. Dis. 75, e380\u2013e388 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"1536_CR124","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03103438 (2016)."},{"key":"1536_CR125","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04397562 (2021)."},{"key":"1536_CR126","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1134\/S1607672924701072","volume":"518","author":"VI Mazurov","year":"2024","unstructured":"Mazurov, V. I. et al. Efficacy and safety of levilimab in combination with methotrexate in patients with active rheumatoid arthritis: 56-week results of phase III randomized double-blind placebo-controlled trial SOLAR. Dokl. Biochem. Biophys. 518, 403\u2013416 (2024).","journal-title":"Dokl. Biochem. Biophys."},{"key":"1536_CR127","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/imr.12392","volume":"270","author":"T Igawa","year":"2016","unstructured":"Igawa, T., Haraya, K. & Hattori, K. Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation. Immunol. Rev. 270, 132\u2013151 (2016).","journal-title":"Immunol. Rev."},{"key":"1536_CR128","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1038\/nbt.1691","volume":"28","author":"T Igawa","year":"2010","unstructured":"Igawa, T. et al. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat. Biotechnol. 28, 1203\u20131207 (2010).","journal-title":"Nat. Biotechnol."},{"key":"1536_CR129","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s40265-020-01380-2","volume":"80","author":"YA Heo","year":"2020","unstructured":"Heo, Y. A. Satralizumab: first approval. Drugs 80, 1477\u20131482 (2020).","journal-title":"Drugs"},{"key":"1536_CR130","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","volume":"381","author":"T Yamamura","year":"2019","unstructured":"Yamamura, T. et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N. Engl. J. Med. 381, 2114\u20132124 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1536_CR131","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","volume":"19","author":"A Traboulsee","year":"2020","unstructured":"Traboulsee, A. et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 19, 402\u2013412 (2020).","journal-title":"Lancet Neurol."},{"key":"1536_CR132","doi-asserted-by":"publisher","first-page":"104025","DOI":"10.1016\/j.msard.2022.104025","volume":"66","author":"T Yamamura","year":"2022","unstructured":"Yamamura, T. et al. Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar. Mult. Scler. Relat. Disord. 66, 104025 (2022).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1536_CR133","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.2217\/nnm.13.86","volume":"8","author":"G Hassanzadeh-Ghassabeh","year":"2013","unstructured":"Hassanzadeh-Ghassabeh, G., Devoogdt, N., De Pauw, P., Vincke, C. & Muyldermans, S. Nanobodies and their potential applications. Nanomedicine 8, 1013\u20131026 (2013).","journal-title":"Nanomedicine"},{"key":"1536_CR134","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13075-015-0651-0","volume":"17","author":"M Van Roy","year":"2015","unstructured":"Van Roy, M. et al. The preclinical pharmacology of the high affinity anti-IL-6R Nanobody(R) ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res. Ther. 17, 135 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"1536_CR135","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1002\/art.38091","volume":"65","author":"JC Szepietowski","year":"2013","unstructured":"Szepietowski, J. C. et al. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis Rheum. 65, 2661\u20132671 (2013).","journal-title":"Arthritis Rheum."},{"key":"1536_CR136","doi-asserted-by":"publisher","first-page":"187","DOI":"10.5414\/CP201785","volume":"51","author":"Y Zhuang","year":"2013","unstructured":"Zhuang, Y. et al. Pharmacokinetics and safety of sirukumab following a single subcutaneous administration to healthy Japanese and Caucasian subjects. Int. J. Clin. Pharmacol. Ther. 51, 187\u2013199 (2013).","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"1536_CR137","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1136\/annrheumdis-2013-205137","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen, J. S., Weinblatt, M. E., Sheng, S., Zhuang, Y. & Hsu, B. Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann. Rheum. Dis. 73, 1616\u20131625 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"1536_CR138","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1136\/annrheumdis-2011-200704","volume":"71","author":"P Mease","year":"2012","unstructured":"Mease, P. et al. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Ann. Rheum. Dis. 71, 1183\u20131189 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"1536_CR139","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT01490450 (2021)."},{"key":"1536_CR140","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT01403064 (2021)."},{"key":"1536_CR141","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03744910 (2025)."},{"key":"1536_CR142","doi-asserted-by":"publisher","first-page":"sfaf108","DOI":"10.1093\/ckj\/sfaf108","volume":"18","author":"M Kanbay","year":"2025","unstructured":"Kanbay, M. et al. Targeting IL-6 in antibody-mediated kidney transplant rejection. Clin. Kidney J. 18, sfaf108 (2025).","journal-title":"Clin. Kidney J."},{"key":"1536_CR143","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05485961 (2026)."},{"key":"1536_CR144","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1038\/s41591-024-03043-1","volume":"30","author":"GM Chertow","year":"2024","unstructured":"Chertow, G. M. et al. IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial. Nat. Med. 30, 2328\u20132336 (2024).","journal-title":"Nat. Med."},{"key":"1536_CR145","doi-asserted-by":"publisher","first-page":"3659","DOI":"10.1158\/1078-0432.CCR-12-3349","volume":"19","author":"R Kurzrock","year":"2013","unstructured":"Kurzrock, R. et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin. Cancer Res. 19, 3659\u20133670 (2013).","journal-title":"Clin. Cancer Res."},{"key":"1536_CR146","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1158\/1078-0432.CCR-13-2200","volume":"20","author":"E Angevin","year":"2014","unstructured":"Angevin, E. et al. A phase I\/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. Clin. Cancer Res. 20, 2192\u20132204 (2014).","journal-title":"Clin. Cancer Res."},{"key":"1536_CR147","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1136\/gutjnl-2017-314562","volume":"68","author":"S Danese","year":"2019","unstructured":"Danese, S. et al. Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn\u2019s disease (ANDANTE I and II). Gut 68, 40\u201348 (2019).","journal-title":"Gut"},{"key":"1536_CR148","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1111\/bcp.13641","volume":"84","author":"C Li","year":"2018","unstructured":"Li, C., Shoji, S. & Beebe, J. Pharmacokinetics and C-reactive protein modelling of anti-interleukin-6 antibody (PF-04236921) in healthy volunteers and patients with autoimmune disease. Br. J. Clin. Pharmacol. 84, 2059\u20132074 (2018).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"1536_CR149","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1136\/annrheumdis-2016-209668","volume":"76","author":"DJ Wallace","year":"2017","unstructured":"Wallace, D. J. et al. Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. Ann. Rheum. Dis. 76, 534\u2013542 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"1536_CR150","unstructured":"Kulkarni, S. Tourmaline Bio, Inc. FORM 10-Q. https:\/\/ir.tourmalinebio.com\/static-files\/256a12b5-a611-4d17-9f35-eabe946ec437 (Tourmaline Bio, 2025)."},{"key":"1536_CR151","unstructured":"Mishek, S. Tourmaline Bio announces positive topline results from the ongoing phase 2 TRANQUILITY trial evaluating pacibekitug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease. Tourmaline release details. https:\/\/ir.tourmalinebio.com\/news-releases\/news-release-details\/tourmaline-bio-announces-positive-topline-results-ongoing-phase (Tourmaline Bio, 2025)."},{"key":"1536_CR152","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03926117 (2025)."},{"key":"1536_CR153","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.jmb.2011.06.031","volume":"411","author":"DK Finch","year":"2011","unstructured":"Finch, D. K. et al. Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics. J. Mol. Biol. 411, 791\u2013807 (2011).","journal-title":"J. Mol. Biol."},{"key":"1536_CR154","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40259-021-00471-0","volume":"35","author":"S Ko","year":"2021","unstructured":"Ko, S., Jo, M. & Jung, S. T. Recent achievements and challenges in prolonging the serum half-lives of therapeutic IgG antibodies through Fc engineering. BioDrugs 35, 147\u2013157 (2021).","journal-title":"BioDrugs"},{"key":"1536_CR155","doi-asserted-by":"publisher","first-page":"224","DOI":"10.34067\/KID.0005862020","volume":"2","author":"KL Nowak","year":"2021","unstructured":"Nowak, K. L. et al. A phase 1 randomized dose-escalation study of a human monoclonal antibody to IL-6 in CKD. Kidney360 2, 224\u2013235 (2021).","journal-title":"Kidney360"},{"key":"1536_CR156","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","volume":"397","author":"PM Ridker","year":"2021","unstructured":"Ridker, P. M. et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 397, 2060\u20132069 (2021).","journal-title":"Lancet"},{"key":"1536_CR157","doi-asserted-by":"publisher","first-page":"617265","DOI":"10.3389\/fphar.2021.617265","volume":"12","author":"X Tang","year":"2021","unstructured":"Tang, X., Zeng, X., Guan, X., Chen, R. & Hu, P. Modeling and simulation to support phase Ib\/IIa dose selection for WBP216, a long half-life fully human monoclonal antibody against interleukin-6. Front. Pharmacol. 12, 617265 (2021).","journal-title":"Front. Pharmacol."},{"key":"1536_CR158","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05021835 (2026)."},{"key":"1536_CR159","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06118281 (2026)."},{"key":"1536_CR160","unstructured":"James-Brown, A. Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation. https:\/\/www.novonordisk.com\/content\/nncorp\/global\/en\/news-and-media\/news-and-ir-materials\/news-details.html?id=916587 (2026)."},{"key":"1536_CR161","first-page":"2609","volume":"65","author":"EB Suhler","year":"2024","unstructured":"Suhler, E. B. et al. IL-6 inhibition with vamikibart in patients with uveitic macular edema: phase 3 MEERKAT and SANDCAT trials Invest. Ophthalmol. Vis. Sci. 65, 2609 (2024).","journal-title":"Ophthalmol. Vis. Sci."},{"key":"1536_CR162","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05151744 (2025)."},{"key":"1536_CR163","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05642325 (2026)."},{"key":"1536_CR164","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06771271 (2025)."},{"key":"1536_CR165","unstructured":"Community Register of Orphan Medicinal Products. Policies, Information and Services https:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/o3046.htm (European Commission, 2025)."},{"key":"1536_CR166","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1001\/jamaophthalmol.2026.0610","volume":"144","author":"S Sharma","year":"2026","unstructured":"Sharma, S. et al. Interleukin 6 inhibition with vamikibart for uveitic macular edema: the phase 1 DOVETAIL nonrandomized clinical trial. JAMA Ophthalmol. 144, 442\u2013451 (2026).","journal-title":"JAMA Ophthalmol."},{"key":"1536_CR167","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/cpdd.121","volume":"3","author":"K Kretsos","year":"2014","unstructured":"Kretsos, K. et al. Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: a randomized phase I study. Clin. Pharmacol. Drug. Dev. 3, 388\u2013395 (2014).","journal-title":"Clin. Pharmacol. Drug. Dev."},{"key":"1536_CR168","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1136\/annrheumdis-2013-204760","volume":"73","author":"MC Genovese","year":"2014","unstructured":"Genovese, M. C. et al. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised phase IIb study. Ann. Rheum. Dis. 73, 1607\u20131615 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"1536_CR169","unstructured":"Seegert, D., Schreiber, S., Rose-John, S., W\u00e4tzig, G. H. & Rahaus, N. PEGylated soluble gp130-dimers useful as a medicament. PCT\/EP2004\/006787. https:\/\/patentscope.wipo.int\/search\/en\/WO2004113383 (WIPO, 2004)."},{"key":"1536_CR170","unstructured":"Seegert, D. & W\u00e4tzig, G. H. Soluble gp130 molecule variants useful as a medicament. PCT\/EP2006\/012515. https:\/\/patentscope.wipo.int\/search\/en\/WO2007071449 (WIPO, 2006)."},{"key":"1536_CR171","unstructured":"W\u00e4tzig, G. H. & Seegert, D. Improved sgp130Fc dimers. PCT\/EP2007\/005812. https:\/\/patentscope.wipo.int\/search\/en\/WO2008000516 (WIPO, 2007)."},{"key":"1536_CR172","doi-asserted-by":"publisher","first-page":"27200","DOI":"10.1074\/jbc.M803694200","volume":"283","author":"S Tenhumberg","year":"2008","unstructured":"Tenhumberg, S. et al. Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130. J. Biol. Chem. 283, 27200\u201327207 (2008).","journal-title":"J. Biol. Chem."},{"key":"1536_CR173","unstructured":"Gr\u00f6tzinger, J., Scheller, J., Tenhumberg, S., Rose-John, S. & W\u00e4tzig, G. H. Soluble gp130 molecule variants useful as a medicament. PCT\/EP2008\/008736. https:\/\/patentscope.wipo.int\/search\/en\/WO2009049881 (WIPO, 2008)."},{"key":"1536_CR174","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13832","volume":"17","author":"FD Wagner","year":"2024","unstructured":"Wagner, F. D. et al. Safety, tolerability, and pharmacokinetics of single- and multiple-ascending doses of olamkicept: Results from randomized, placebo-controlled, first-in-human phase I trials. Clin. Transl. Sci. 17, e13832 (2024). This study reported the first phase I trials of olamkicept, which was safe and well tolerated.","journal-title":"Clin. Transl. Sci."},{"key":"1536_CR175","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70674","volume":"19","author":"S Ignatenko","year":"2026","unstructured":"Ignatenko, S. et al. Safety and pharmacokinetics of single and multiple ascending doses of olamkicept up to 2400\u2009mg in healthy men: phase I, randomized, placebo-controlled, and double-blind trial. Clin. Transl. Sci. 19, e70674 (2026).","journal-title":"Clin. Transl. Sci."},{"key":"1536_CR176","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1053\/j.gastro.2021.02.062","volume":"160","author":"S Schreiber","year":"2021","unstructured":"Schreiber, S. et al. Therapeutic Interleukin-6 trans-signaling inhibition by olamkicept (sgp130Fc) in patients with active inflammatory bowel disease. Gastroenterology 160, 2354\u20132366.e2311 (2021). This study reports proof of mechanism and clinical efficacy of olamkicept in a phase IIa trial in patients with inflammatory bowel disease.","journal-title":"Gastroenterology"},{"key":"1536_CR177","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1001\/jama.2023.1084","volume":"329","author":"S Zhang","year":"2023","unstructured":"Zhang, S. et al. Effect of induction therapy with olamkicept vs placebo on clinical response in patients with active ulcerative colitis: a randomized clinical trial. JAMA 329, 725\u2013734 (2023). This study describes that olamkicept was highly effective in a phase IIb trial in patients with ulcerative colitis.","journal-title":"JAMA"},{"key":"1536_CR178","doi-asserted-by":"publisher","first-page":"120105","DOI":"10.1016\/j.bbamcr.2026.120105","volume":"1873","author":"I Ramon Roth","year":"2026","unstructured":"Ramon Roth, I., Fuhring, J. I. & Garbers, C. Understanding complex formation of gp130 cytokines for the design of selective therapeutics. Biochim. Biophys. Acta. Mol. Cell Res. 1873, 120105 (2026).","journal-title":"Biochim. Biophys. Acta. Mol. Cell Res."},{"key":"1536_CR179","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nbt.1601","volume":"28","author":"J Zalevsky","year":"2010","unstructured":"Zalevsky, J. et al. Enhanced antibody half-life improves in vivo activity. Nat. Biotechnol. 28, 157\u2013159 (2010).","journal-title":"Nat. Biotechnol."},{"key":"1536_CR180","doi-asserted-by":"publisher","first-page":"100058","DOI":"10.1016\/j.cytox.2021.100058","volume":"3","author":"AF Berg","year":"2021","unstructured":"Berg, A. F. et al. Exclusive inhibition of IL-6 trans-signaling by soluble gp130(FlyR)Fc. Cytokine X 3, 100058 (2021).","journal-title":"Cytokine X"},{"key":"1536_CR181","doi-asserted-by":"publisher","first-page":"26943","DOI":"10.1074\/jbc.M115.682138","volume":"290","author":"M Lacroix","year":"2015","unstructured":"Lacroix, M. et al. Novel insights into interleukin 6 (IL-6) cis- and trans-signaling pathways by differentially manipulating the assembly of the IL-6 signaling complex. J. Biol. Chem. 290, 26943\u201326953 (2015).","journal-title":"J. Biol. Chem."},{"key":"1536_CR182","doi-asserted-by":"publisher","first-page":"42959","DOI":"10.1074\/jbc.M111.295758","volume":"286","author":"C Garbers","year":"2011","unstructured":"Garbers, C. et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J. Biol. Chem. 286, 42959\u201342970 (2011).","journal-title":"J. Biol. Chem."},{"key":"1536_CR183","doi-asserted-by":"publisher","first-page":"6762","DOI":"10.1074\/jbc.RA117.001163","volume":"293","author":"P Baran","year":"2018","unstructured":"Baran, P. et al. The balance of interleukin (IL)-6, IL-6.soluble IL-6 receptor (sIL-6R), and IL-6.sIL-6R.sgp130 complexes allows simultaneous classic and trans-signaling. J. Biol. Chem. 293, 6762\u20136775 (2018).","journal-title":"J. Biol. Chem."},{"key":"1536_CR184","unstructured":"Lofquist, A. K., Misher, L., Adamo, J. B., Fang, H. & Ravikumar, P. Anti-sIL6XR complex binding domains and methods of use. PCT\/US2012\/065679. https:\/\/patentscope.wipo.int\/search\/en\/WO2013075027 (WIPO, 2012)."},{"key":"1536_CR185","unstructured":"Clark, A. & Wijdenes, J. Antibodies binding to human interleukin-6 receptor. PCT\/EP2024\/053654. https:\/\/patentscope.wipo.int\/search\/en\/WO2024170583 (WIPO, 2024)."},{"key":"1536_CR186","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1136\/gutjnl-2023-330000","volume":"75","author":"S Schreiber","year":"2025","unstructured":"Schreiber, S., Aden, K., Tran, F. & Rosenstiel, P. Rise of precision medicine: can it deliver on its promise in IBD? Gut 75, 176\u2013188 (2025).","journal-title":"Gut"},{"key":"1536_CR187","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT01545050 (2021)."},{"key":"1536_CR188","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrrheum.2017.83","volume":"13","author":"S Rose-John","year":"2017","unstructured":"Rose-John, S., Winthrop, K. & Calabrese, L. The role of IL-6 in host defence against infections: immunobiology and clinical implications. Nat. Rev. Rheumatol. 13, 399\u2013409 (2017).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1536_CR189","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119\u20131131 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1536_CR190","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S2468-1253(24)00044-X","volume":"9","author":"N Chanchlani","year":"2024","unstructured":"Chanchlani, N. et al. Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn\u2019s disease: 3-year data from the prospective, multicentre PANTS cohort study. Lancet Gastroenterol. Hepatol. 9, 521\u2013538 (2024).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1536_CR191","doi-asserted-by":"publisher","first-page":"23","DOI":"10.5152\/eurjrheum.2018.18078","volume":"6","author":"P Polak","year":"2019","unstructured":"Polak, P. et al. A single-arm, open-label study to assess the immunogenicity, safety, and efficacy of etanercept manufactured using the serum-free, high-capacity manufacturing process administered to patients with rheumatoid arthritis. Eur. J. Rheumatol. 6, 23\u201328 (2019).","journal-title":"Eur. J. Rheumatol."},{"key":"1536_CR192","doi-asserted-by":"publisher","unstructured":"Schreiber, S. et al. Comparing outcomes with subcutaneous infliximab (CT-P13 SC) by baseline immunosuppressant use: a post hoc analysis of the LIBERTY-CD and LIBERTY-UC studies. Inflamm. Bowel Dis. 31, 2714\u20132724 https:\/\/doi.org\/10.1093\/ibd\/izaf038 (2025).","DOI":"10.1093\/ibd\/izaf038"},{"key":"1536_CR193","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","volume":"160","author":"S Schreiber","year":"2021","unstructured":"Schreiber, S. et al. Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease. Gastroenterology 160, 2340\u20132353 (2021).","journal-title":"Gastroenterology"},{"key":"1536_CR194","doi-asserted-by":"publisher","unstructured":"Sands, B. E. et al. Endoscopic response to subcutaneous infliximab by disease location: a post hoc analysis of the LIBERTY-CD study. Clin. Gastroenterol. Hepatol. 24, 1111\u20131120 https:\/\/doi.org\/10.1016\/j.cgh.2025.11.017 (2025).","DOI":"10.1016\/j.cgh.2025.11.017"},{"key":"1536_CR195","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1093\/ibd\/izaf163","volume":"31","author":"S Schreiber","year":"2025","unstructured":"Schreiber, S. et al. Ustekinumab intravenous reinduction after secondary loss of response in patients with Crohn\u2019s disease. Inflamm. Bowel Dis. 31, 3286\u20133297 (2025).","journal-title":"Inflamm. Bowel Dis."},{"key":"1536_CR196","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.ard.2025.01.049","volume":"84","author":"R Zorc","year":"2025","unstructured":"Zorc, R. et al. A coding single nucleotide polymorphism in the interleukin-6 receptor enhances IL-6 signalling in CD4 T cells and predicts treatment response to tocilizumab in giant cell arteritis. Ann. Rheum. Dis. 84, 1401\u20131411 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"1536_CR197","doi-asserted-by":"publisher","first-page":"8389","DOI":"10.2147\/JIR.S524632","volume":"18","author":"P Krawiec","year":"2025","unstructured":"Krawiec, P., Lejman, M. & Pac-Kozuchowska, E. The association of polymorphisms in interleukin-6 (IL-6), interleukin-10 (IL-10), IL-6 receptor, and IL-10 receptor genes with the risk of pediatric inflammatory bowel disease. J. Inflamm. Res. 18, 8389\u20138397 (2025).","journal-title":"J. Inflamm. Res."},{"key":"1536_CR198","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.regpep.2007.09.031","volume":"146","author":"A Benrick","year":"2008","unstructured":"Benrick, A. et al. A non-conservative polymorphism in the IL-6 signal transducer (IL6ST)\/gp130 is associated with myocardial infarction in a hypertensive population. Regul. Pept. 146, 189\u2013196 (2008).","journal-title":"Regul. Pept."},{"key":"1536_CR199","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/ueg2.12686","volume":"12","author":"S Schreiber","year":"2024","unstructured":"Schreiber, S. et al. Distinct trajectories of symptomatic response in ulcerative colitis during filgotinib therapy: a post hoc analysis from the SELECTION study. U Eur. Gastroenterol. J. 12, 1243\u20131255 (2024).","journal-title":"U Eur. Gastroenterol. J."},{"key":"1536_CR200","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamadermatol.2024.2463","volume":"160","author":"K Eyerich","year":"2024","unstructured":"Eyerich, K. et al. Noninferiority of 16-week vs 8-week guselkumab dosing in super responders for maintaining control of psoriasis: the GUIDE randomized clinical trial. JAMA Dermatol. 160, 953\u2013963 (2024).","journal-title":"JAMA Dermatol."},{"key":"1536_CR201","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1182\/blood-2007-01-067918","volume":"110","author":"A Chalaris","year":"2007","unstructured":"Chalaris, A. et al. Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood 110, 1748\u20131755 (2007).","journal-title":"Blood"},{"key":"1536_CR202","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1182\/blood-2007-07-102137","volume":"111","author":"B Rabe","year":"2008","unstructured":"Rabe, B. et al. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 111, 1021\u20131028 (2008).","journal-title":"Blood"},{"key":"1536_CR203","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1002\/art.38061","volume":"65","author":"E Tsantikos","year":"2013","unstructured":"Tsantikos, E. et al. Interleukin-6 trans-signaling exacerbates inflammation and renal pathology in lupus-prone mice. Arthritis Rheum. 65, 2691\u20132702 (2013).","journal-title":"Arthritis Rheum."},{"key":"1536_CR204","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1164\/rccm.201512-2368OC","volume":"194","author":"SM Ruwanpura","year":"2016","unstructured":"Ruwanpura, S. M. et al. Therapeutic targeting of the IL-6 trans-signalling\/mTORC1 axis in pulmonary emphysema. Am. J. Respir. Crit. Care Med. 194, 1494\u20131505 (2016).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1536_CR205","doi-asserted-by":"publisher","first-page":"2002248","DOI":"10.1183\/13993003.02248-2020","volume":"59","author":"D Hirani","year":"2022","unstructured":"Hirani, D. et al. Macrophage-derived IL-6 trans-signalling as a novel target in the pathogenesis of bronchopulmonary dysplasia. Eur. Respir. J. 59, 2002248 (2022).","journal-title":"Eur. Respir. J."},{"key":"1536_CR206","doi-asserted-by":"publisher","first-page":"eadh0831","DOI":"10.1126\/sciadv.adh0831","volume":"9","author":"E Boslem","year":"2023","unstructured":"Boslem, E. et al. Therapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC. Sci. Adv. 9, eadh0831 (2023).","journal-title":"Sci. Adv."},{"key":"1536_CR207","doi-asserted-by":"publisher","first-page":"114974","DOI":"10.1016\/j.celrep.2024.114974","volume":"43","author":"B Curren","year":"2024","unstructured":"Curren, B. et al. A maternal high-fat diet predisposes to infant lung disease via increased neutrophil-mediated IL-6 trans-signaling. Cell Rep. 43, 114974 (2024).","journal-title":"Cell Rep."},{"key":"1536_CR208","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/febs.17355","volume":"292","author":"S Rose-John","year":"2025","unstructured":"Rose-John, S. & Jones, S. A. More and more pleiotropy within the IL-6 family of cytokines. FEBS J. 292, 519\u2013522 (2025).","journal-title":"FEBS J."},{"key":"1536_CR209","doi-asserted-by":"publisher","first-page":"4672","DOI":"10.4049\/jimmunol.164.9.4672","volume":"164","author":"J Mullberg","year":"2000","unstructured":"Mullberg, J. et al. IL-6 receptor independent stimulation of human gp130 by viral IL-6. J. Immunol. 164, 4672\u20134677 (2000).","journal-title":"J. Immunol."},{"key":"1536_CR210","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.cytogfr.2015.07.006","volume":"26","author":"HM Hermanns","year":"2015","unstructured":"Hermanns, H. M. & Oncostatin, M. and interleukin-31: cytokines, receptors, signal transduction and physiology. Cytokine Growth Factor. Rev. 26, 545\u2013558 (2015).","journal-title":"Cytokine Growth Factor. Rev."},{"key":"1536_CR211","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cytogfr.2012.04.001","volume":"23","author":"C Garbers","year":"2012","unstructured":"Garbers, C. et al. Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor. Rev. 23, 85\u201397 (2012).","journal-title":"Cytokine Growth Factor. Rev."},{"key":"1536_CR212","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/febs.17309","volume":"292","author":"HT Weitz","year":"2025","unstructured":"Weitz, H. T. et al. Interleukin-11 receptor is an alternative alpha-receptor for interleukin-6 and the chimeric cytokine IC7. FEBS J. 292, 523\u2013536 (2025).","journal-title":"FEBS J."},{"key":"1536_CR213","doi-asserted-by":"publisher","first-page":"107251","DOI":"10.1016\/j.jbc.2024.107251","volume":"300","author":"P Rafii","year":"2024","unstructured":"Rafii, P. et al. Engineered interleukin-6-derived cytokines recruit artificial receptor complexes and disclose CNTF signaling via the OSMR. J. Biol. Chem. 300, 107251 (2024).","journal-title":"J. Biol. Chem."},{"key":"1536_CR214","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.bbrc.2004.11.098","volume":"326","author":"J Scheller","year":"2005","unstructured":"Scheller, J., Schuster, B., Holscher, C., Yoshimoto, T. & Rose-John, S. No inhibition of IL-27 signaling by soluble gp130. Biochem. Biophys. Res. Commun. 326, 724\u2013728 (2005).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1536_CR215","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/j.celrep.2016.01.053","volume":"14","author":"J Lokau","year":"2016","unstructured":"Lokau, J. et al. Proteolytic cleavage governs interleukin-11 trans-signaling. Cell Rep. 14, 1761\u20131773 (2016).","journal-title":"Cell Rep."},{"key":"1536_CR216","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.cyto.2017.01.015","volume":"92","author":"JJ Balic","year":"2017","unstructured":"Balic, J. J., Garbers, C., Rose-John, S., Yu, L. & Jenkins, B. J. Interleukin-11-driven gastric tumourigenesis is independent of trans-signalling. Cytokine 92, 118\u2013123 (2017).","journal-title":"Cytokine"},{"key":"1536_CR217","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202515772","volume":"13","author":"H Yang","year":"2026","unstructured":"Yang, H. et al. Triple-negative breast cancer cells resist natural killer cell-mediated killing through interleukin-11 trans-signaling. Adv. Sci. 13, e15772 (2026).","journal-title":"Adv. Sci."},{"key":"1536_CR218","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2147\/ITT.S485684","volume":"14","author":"T Schumertl","year":"2025","unstructured":"Schumertl, T., Lokau, J. & Garbers, C. IL-6 signaling in immunopathology: from basic biology to selective therapeutic intervention. Immunotargets Ther. 14, 681\u2013695 (2025).","journal-title":"Immunotargets Ther."},{"key":"1536_CR219","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/S0140-6736(12)61246-X","volume":"380","author":"J Scheller","year":"2012","unstructured":"Scheller, J. & Rose-John, S. The interleukin 6 pathway and atherosclerosis. Lancet 380, 338 (2012).","journal-title":"Lancet"},{"key":"1536_CR220","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.2000080","volume":"15","author":"S Riethmueller","year":"2017","unstructured":"Riethmueller, S. et al. Proteolytic origin of the soluble human IL-6R in vivo and a decisive role of N-glycosylation. PLoS Biol. 15, e2000080 (2017).","journal-title":"PLoS Biol."},{"key":"1536_CR221","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.bbadis.2014.05.018","volume":"1842","author":"C Garbers","year":"2014","unstructured":"Garbers, C. et al. The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases. Biochim. Biophys. Acta 1842, 1485\u20131494 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"1536_CR222","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.125.005103","volume":"18","author":"E deGoma","year":"2025","unstructured":"deGoma, E., Walsh, J. & Georgakis, M. K. Human genetics informing drug development in cardiovascular disease: interleukin-6 signaling as a case study. Circ. Genom. Precis. Med. 18, e005103 (2025).","journal-title":"Circ. Genom. Precis. Med."}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01536-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01536-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01536-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:08:42Z","timestamp":1790176122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01536-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":222,"alternative-id":["1536"],"URL":"https:\/\/doi.org\/10.1038\/s41573-026-01536-x","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"25 August 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.R.-J. is a co-inventor of IP owned by CONARIS Research Institute AG, a company that owns the IP rights to olamkicept, is a member of CONARIS\u2019 supervisory board and has acted as a consultant for AbbVie, Chugai, Genentech Roche, Regeneron, Roche, Pfizer, Sanofi and ZipBio regarding the use of interleukin-6 blockade with other agents. G.H.W. is employed part-time by CONARIS and is a co-inventor of CONARIS\u2019 IP. S.S. has received personal fees from AbbVie, Amgen, Arena, Biogen, Bristol Meyers Squibb, Bristol Meyers Squibb, Celgene, Celltrion, Falk, Ferring, Fresenius Kabi, Galapagos, Gilead, IMAB, Janssen, Lilly, MSD, Mylan, Novartis, Pfizer, Protagonist, Provention Bio, Roche, Sandoz\/Hexal, Shire, Takeda and Ventyx. S.S. is a co-inventor of IP owned by CONARIS, is a member of CONARIS\u2019 supervisory board and has consulted with Pfizer, Bristol Myers Squibb and Roche regarding the use of interleukin-6 blockade with other agents.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}